Chenglong Li PhD

Chenglong Li PhD
Assoc ProfessorCollege of Pharmacyli.728@osu.edu
612 Riffe Building 496 W 12th Avenue Columbus Ohio 43210
Phone:614-247-8786Fax: (614) 292-2435
  • Translational Therapeutics

General Research Interest

Structure-based drug design, Computational drug design and discovery, Molecular recognition, Computational chemistry, X-ray protein crystallography.

Research Description

My research focus is drug-target interaction at the molecular level. I combine computational molecular design with X-ray crystallography to do structure-based drug design and discovery. Currently, my cancer related projects are: 1) IL-6/JAK2/STAT3 signaling pathway. The design focus is to target the STAT3 SH2 domain to prevent STAT3 phosphorylation and dimerization; and to disrupt IL-6/IL-6R/gp130 functional complex. 2) DNMT1 and PRMT5. The design focus is to inhibit DNMT1 and PRMT5 catalytic sites from DNA and histone epigenetic methylations

Transinstitutional Work

Current trans-institutional work include: 1) collaborations with Drs. Tushar Patel, Greg Lesinski and Don Benson at College of Medicine, and Dr. Jiayuh Lin at the Nationwide Children’s hospital Columbus on anti-cancer drug discovery targeting IL-6/STAT3 oncogenic pathway; 2) collaboration with Dr. Rob Baiocchi at College of Medicine on anti-cancer drug discovery targeting PRMT5 epigenetic enzyme; 3) collaboration with Dr. Xiaodong Wang at the University of Toledo on drug design targeting CFTR to fight cystic fibrosis.

Current Publications

  • Li C, Wang Y, Harvey W, Park IH, Rübel O, Pascucci V, Bremer PTA collaborative visual analytics suite for protein folding research.J Mol Graph Model in press 59-71 7/14/2014
  • Yan F, Alinari L, Lustberg ME, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon KGenetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Lai H, Gallucci JC, Li CN-[2-(9H-Carbazol-9-yl)eth-yl]-4-(methyl-sulfon-yl)aniline.Acta Crystallogr Sect E Struct Rep Online 70 o332 3/1/2014
  • Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li CDrug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.J Med Chem 57 632-41 2/13/2014
  • Lai H, Gallucci JC, Li C(E)-3-(9-Ethyl-9H-carbazol-3-yl)-1-(2-meth-oxy-phen-yl)prop-2-en-1-one.Acta Crystallogr Sect E Struct Rep Online 70 o190 2/1/2014
  • Wang XR, Li CDecoding f508del misfolding in cystic fibrosis.Biomolecules 4 498-509 1/1/2014
  • He X, Rao W, Zhang W, Poventud-Fuentes I, Wang Y, Lei Y, Agarwal P, Weekes B, Li C, Lu X, Yu JThermally Responsive Nanoparticle-Encapsulated Curcumin and Its Combination with Mild Hyperthermia for Enhanced Cancer Cell Destruction.Acta Biomater in press 10/26/2013
  • Li J, Pan L, Deng Y, Muñoz-Acuña U, Yuan C, Lai H, Chai H, Chagwedera TE, Farnsworth NR, Carcache de Blanco EJ, Li C, Soejarto DD, Kinghorn ADSphenostylisins A-K: bioactive modified isoflavonoid constituents of the root bark of Sphenostylis marginata ssp. erecta.J Org Chem 78 10166-77 10/18/2013
  • Chettiar SN, Cooley JV, Park IH, Bhasin D, Chakravarti A, Li PK, Li C, Jacob NKDesign, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle.Bioorg Med Chem Lett 23 5429-33 10/1/2013
  • Yi B, Long S, González-Cestari TF, Henderson BJ, Pavlovicz RE, Werbovetz K, Li C, McKay DBDiscovery of benzamide analogs as negative allosteric modulators of human neuronal nicotinic receptors: pharmacophore modeling and structure-activity relationship studies.Bioorg Med Chem 21 4730-43 8/1/2013
  • Yu W, Xiao H, Lin J, Li CDiscovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.J Med Chem 56 4402-12 6/13/2013
  • Mahasenan KV, Agarwal H, Li C, Endeshaw M, Zhu X, He S, Pandharkar T, Cason E, Munde M, Wilson WD, Bahar M, Doskotch RW, Kinghorn AD, Kaiser M, Brun R, Drew ME, Werbovetz KA8,8-dialkyldihydroberberines with potent antiprotozoal activity.J Nat Prod 76 311-5 3/22/2013
  • Yu W, Li C4-Nitro-phenyl N-(2-sulfamoylphen-yl)carbamate.Acta Crystallogr Sect E Struct Rep Online 69 o355 3/1/2013
  • Still PC, Yi B, González-Cestari TF, Pan L, Pavlovicz RE, Chai HB, Ninh TN, Li C, Soejarto DD, McKay DB, Kinghorn ADAlkaloids from Microcos paniculata with cytotoxic and nicotinic receptor antagonistic activities.J Nat Prod 76 243-9 2/22/2013
  • Liu MJ, Bao S, Gálvez-Peralta M, Pyle CJ, Rudawsky AC, Pavlovicz RE, Killilea DW, Li C, Nebert DW, Wewers MD, Knoell DLZIP8 regulates host defense through zinc-mediated inhibition of NF-κB.Cell Rep 3 386-400 2/21/2013
  • Kurt H, Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin D, Chettiar S, Kitange G, Park IH, Sarkaria JN, Li C, Shakhparonov MI, Nakano I, Guvenc H, Pavlyukov MS, Joshi KImpairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex.Clin Cancer Res 19 631-42 2/1/2013
  • Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CMHeat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.Blood 121 351-9 1/10/2013
  • Frey EN, Pavlovicz RE, Wegman CJ, Li C, Askwith CCConformational changes in the lower palm domain of ASIC1a contribute to desensitization and RFamide modulation.PLoS One 8 e71733 1/1/2013
  • Lin L, Hutzen B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, Korkaya H, Wicha MS, Lin JEvaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.PLoS One 8 e82821 1/1/2013
  • Anderson ME, Mohler PJ, Hund TJ, Koval OM, Snyder JS, Wolf RM, Pavlovicz RE, Glynn P, Curran J, Leymaster ND, Dun W, Wright PJ, Cardona N, Qian L, Mitchell CC, Boyden PA, Binkley PF, Li CCa2+/calmodulin-dependent protein kinase II-based regulation of voltage-gated Na+ channel in cardiac disease.Circulation 126 2084-94 10/23/2012
  • Henderson BJ, González-Cestari TF, Yi B, Pavlovicz RE, Boyd RT, Li C, Bergmeier SC, McKay DBDefining the putative inhibitory site for a selective negative allosteric modulator of human α4β2 neuronal nicotinic receptors.ACS Chem Neurosci 3 682-92 9/19/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu